Skip to main content

Select Drug Profiles

Leukemia, Oncology
First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation
Charles Bankhead
Charles Bankhead
Read More
Leukemia, Oncology
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
Phoebe Starr
Read More
Lymphoma
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
Phoebe Starr
Read More
Immunotherapy, Oncology
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
Phoebe Starr
Read More
Immunotherapy, Oncology
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
Phoebe Starr
Phoebe Starr
Read More
Immunotherapy, Oncology
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
Phoebe Starr
Read More
Practice Management
High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Chase Doyle
Read More
Leukemia, Oncology
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Phoebe Starr
Read More
Lymphoma
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
Charles Bankhead
Read More
FDA Approvals
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Read More
Page 59 of 244
Results 581 - 590 of 2438